1 COVID-19 Serology in New York State Using a Multiplex Microsphere Immunoassay 2

3

4	Danielle T. Hunt ¹ , Jennifer L. Yates ^{1,2} , Karen E. Kulas ¹ , Kyle Carson ¹ , Theresa Lamson ¹ ,
5	Valerie Demarest ¹ , Andrea Furuya ¹ , Kelly Howard ¹ , Mary Marchewka ¹ , Randy Stone ¹ ,
6	Heidi Tucker ¹ , Casey Warszycki ¹ , Jim Yee ^{3,4} , He S. Yang ^{3,4} , Sabrina Racine-Brzostek ^{3,4} ,
7	Zhen Zhao ^{3,4} , Monir Ejemel ⁵ , Qi Li ⁵ , Yang Wang ⁵ , Sebastian Fernando ⁶ , Francesca La
8	Carpia ⁶ , Eldad A. Hod ⁶ , Kathleen A. McDonough ^{1,2} and William T. Lee ^{1,2} *.
9	

¹Division of Infectious Diseases, Wadsworth Center, New York State Department of 10 Health, Albany, NY, 12208 USA; ²Department of Biomedical Sciences, The School of 11 Public Health, The University at Albany, Albany, NY, 12222 USA; ³Department of 12 Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA; 13 ⁴NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA; 14 ⁵MassBiologics of the University of Massachusetts Medical School, Boston, MA, 9 02126 15 USA; ⁶Department of Pathology and Cell Biology, Columbia University Irving Medical 16 Center, New York, NY, USA 17

18

19

20	Running Head: CoV-2 virus ser	ology at NYSDOH
21		
22		
23	*Address Correspondence to:	Dr. William T. Lee
24		David Axelrod Institute
25		The Wadsworth Center/NYSDOH
26		120 New Scotland Avenue
27		Telephone: (518) 473-3543
28		Email: <u>William.Lee@health.ny.gov</u>
29		
30		
31		
32		
33		
34	Footnotes	
35	¹ Abbreviations: COVID-19,cord	onavirus disease 2019; SARS-CoV-2, Severe acute
36	respiratory syndrome coronaviru	us 2, HuCOV, human endemic (seasonal) coronaviruses;
37	Ab, antibody; (DIL, Diagnostic	Immunology Laboratory at the Wadsworth Center; N,
38	nucleocapsid protein; RBD, rec	eptor-binding domain; MFI, median fluorescent intensity;
39	FDA, Food and Drug Admir	nistration; EUA, Emergency Use Authorization; MIA,
40	microsphere immunoassay	

41 Abstract

42

The emergence of SARS-CoV-2, leading to COVID-19, necessitated the development of 43 new molecular and serological tests. Here, we describe a multiplexed serological assay 44 45 developed as the global pandemic moved into New York State in the spring of 2020. The original microsphere immunoassay used a target antigen from the SARS-CoV-1 virus 46 responsible for the 2003 SARS outbreak, but evolved to incorporate multiple SARS-CoV-47 2 protein antigens (nucleocapsid, spike and spike domains, spike and nucleocapsid 48 49 proteins from seasonal human coronaviruses). Besides being highly versatile due to 50 multiplex capabilities, the assay was highly specific and sensitive and adaptable to measuring both total antibodies and antibody isotypes. While determining the assay 51 52 performance characteristics, we were able to identify antibody production patterns (e.g., 53 kinetics of isotypes, individual variations) for total antibodies and individual antibody classes. Overall, the results provide insights into the laboratory response to new serology 54 needs, and how the evolution and fine-tuning of a serology assay helped contribute to a 55 56 better understanding of the antibody response to SARS-CoV-2.

57 **1.** Introduction

The coronavirus disease 2019 (COVID-19) (1), caused by the Severe Acute Respiratory 58 59 Syndrome Coronavirus 2 (SARS-CoV-2)(2), is historically one of the most widespread and devastating pandemics with severe health, economic, and social consequences (3, 60 4). As a newly emergent virus, knowledge of the resulting disease courses, host 61 62 response characteristics, and the development of diagnostic tests arose only as the pandemic progressed. Still, a strong framework of information was already present 63 from prior studies on other disease-causing coronaviruses, including circulating human 64 endemic coronaviruses (HuCOV), Middle East Respiratory Syndrome virus, and the 65 closely related SARS-CoV-1 (reviewed in (5, 6)). 66

Within the past year there has been an enormous growth in the number of laboratory 67 assays designed to diagnose SARS-CoV-2 infection. These primarily rely on molecular 68 analyses for the detection of viral RNA, and, more recently, serological tests to detect 69 viral antigens and host antibodies (Abs) for the determination of prior exposure to 70 SARS-CoV-2. In particular, there are a wide variety of serology tests with different 71 performance characteristics, different target antigens, and different readouts (7). These 72 tests have clinical, surveillance, and research applications, including information about 73 the COVID-19 disease process and host immune response. 74

The impetus for this study was an exigent need for early development of molecular and serological assays to meet the COVID-19 outbreak in New York State (NYS). As the laboratory arm of the New York State Department of Health, the Wadsworth Center was heavily engaged in assay development and early testing. The Diagnostic Immunology

79 Laboratory at the Wadsworth Center (DIL) initiated an effort to develop a serological assay to identify persons exposed to the novel coronavirus. We developed an initial 80 microsphere immunoassay (MIA) using a Luminex® platform. We determined 81 performance characteristics and implemented the assay for COVID-19 serology testing 82 of sera from NYS residents. This platform is very adaptable which allows the inclusion 83 or replacement of several different target molecules. As described in this report, over 84 the course of the outbreak, we frequently assessed the testing data and made changes 85 as needed, which also helped to improve our understanding of the SARS-CoV-2 86 87 humoral response to infection.

89 2. Results

90 2.1 Establishment of the MIA.

The NYS SARS-CoV-2 MIA was initially conceived during the early phase of the 91 Wuhan COVID-19 outbreak (1). As no SARS CoV-2 proteins were available to us at the 92 beginning of February 2020, the first generation of the assay used the SARS-CoV-1 93 nucleocapsid (N) protein as the target antigen (8). The SARS-CoV-1 N protein, prepared 94 at the Wadsworth Center in 2003 for use in the original SARS outbreak (9), was coupled 95 to microspheres and tested using a guinea pig anti-serum reactive with SARS-CoV-1. 96 The antiserum showed high binding (Figure 1A), while serum from a nonimmune guinea 97 pig did not react. In later experiments employing SARS-CoV-2 antigens and COVID-19 98 99 sera, the same guinea pig anti-SARS-CoV-1 serum showed nearly equivalent binding to the SARS CoV-2 N protein (Figure 1A). Likewise, COVID-19 patient sera were 100 comparably reactive with both SARS-CoV-1 and SARS-CoV-2 N proteins (Figure 1B) 101 102 and, MIAs using either protein as the target antigen behaved equivalently (Figure 1C). The high degree of cross-reactivity between the two N antigens contrasted with our later 103 observations of differential antibody binding to the SARS-CoV-1 and SARS-CoV-2 Spike 104 proteins, as we observed little binding of the SARS-CoV-1 guinea pig serum to the SARS-105 CoV-2 spike proteins (Figure 1D) and, conversely, reduced binding of COVID-19 sera to 106 the SARS-CoV-1 spike protein (Figure 1E and F). 107

108

109 2.2 Specificity of the MIA

medRxiv preprint doi: https://doi.org/10.1101/2021.05.12.21257125; this version posted May 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Assay cutoffs are established as an MFI threshold to determine specimen 110 reactivity. A panel of 92 serum specimens from healthy donors, collected in 2009, were 111 tested for total antibody produced against SARS-CoV-1 N-protein and the cutoff was 112 defined as the mean median fluorescence intensities (MFI) plus three standard deviations 113 (SD) (Figure 2A). An additional 164 specimens were tested, and, of the total of 256, only 114 115 7% of the specimens (93% specificity) were reactive (data not shown). Considering that for endemic seasonal coronaviruses (HCoV-229E, -NL63, -OC43, and -HKU1) there is 116 an estimated rate of up to 15% infections per year in a geographically close region (10), 117 we reasoned that there was little impact in the assay by antibodies to endemic 118 coronaviruses. We next tested a panel of 30 specimens collected 10-20 days post onset 119 of symptoms from patients with diagnosed non-COVID-19 respiratory illnesses, many of 120 whom had documented positive PCR tests for specific pathogens. Several of the 121 specimens in this category were reactive with the SARS-CoV-1 N protein in the first-122 generation MIA, lowering the assay specificity to 67% (Figure 2B). The most notable 123 cross-reactive specimens were those from patients with RT-PCR-confirmed recent 124 exposure to the endemic coronavirus HCoV-NL-63 coronavirus, for which half of the 125 126 tested specimens had reactivity. The overall MFIs of the cross-reactive specimens, including the reactive HCoV-NL-63 specimens, were lower than the majority of signals 127 from COVID-19 specimens (Figure 2C); hence, to allow for a more specific test, even at 128 129 the expense of sensitivity, we raised the cutoff for the assay to 6 SD above the mean MFI of the healthy donor sera. At this level, when measuring total antibodies, the specificity 130 131 was 99.2% (N only). A second-generation MIA was later implemented and used the 132 SARS-Cov-2 N antigen and, to better capture the breadth of responses, the SARS-CoV-

2 receptor-binding domain (RBD) of the spike protein. The overall specificity of this assay 133 was 98.4% (N plus RBD) (Table 1). Including sera containing Abs to known pathogens or 134 autoantigens did not reduce the specificity (Table 1). For clinical test reporting, the 135 specimens with MFI values that fell between 3 SD and 6 SD of the mean MFI of the 136 normal serum specimens were listed as "Indeterminate" (Figure 2C). In the second-137 138 generation MIA, that included the SARS-CoV-2 RBD, when the two target antigens gave different results, the overall result was based on the most positive of either antigen (e.g., 139 indeterminate plus reactive was reported as reactive). Subsequent analyses of the pre-140 141 COVID blood donors showed that there were abundant antibodies to both the N and spike antigens of the seasonal coronaviruses (Supplemental Figure 1), strongly suggesting that 142 non-acute antibodies to the seasonal coronaviruses did not cross-react with the SARS-143 CoV-2 antigens in the MIA. 144

145 2.3 Sensitivity of the MIA

A broad examination of COVID-19 specimens showed that a greater number were 146 reactive as time progressed (Figure 3). Examination of total antibody reactive in the MIA, 147 regardless of using only the N antigen (Figure 3) or both the N and RBD proteins as target 148 antigens (Table 2), showed that the sensitivity of the assay slowly increased with 149 increased time between symptom onset and testing, with a sensitivity of 96.4% 26-30 150 days following symptom onset (Table 2). Notably, at the time the initial MIA (based upon 151 SARS-CoV-1 N antigen) was submitted to the Food and Drug Administration (FDA) for 152 Emergency Use Authorization (EUA), the maximum days of post symptom onset available 153 to us was 25 days, in which only 88% of the specimens had N-specific antibodies detected 154

by the MIA above the 6SD cutoff (EUA: https://www.fda.gov/media/137541/download). 155 Hence, the initial (FDA) published sensitivity of our N antigen MIA was 88%. Subsequent 156 testing of specimens with >30 days post symptom onset, showed that the assay could 157 detect a much higher percentage of positive specimens. For example, an analysis of 158 8659 COVID-19 convalescent sera (collected 30-50 days post symptom onset) showed 159 160 that the assay had a 92.2% (N antigen-reactive) sensitivity using the 6 SD cutoff, compared to 95.9% using 3 SD (Table 3). This study also showed the impact of adding 161 additional antigens, such as the RBD, into the MIA. Comparison of separate reactivity to 162 163 the N and the RBD proteins within the same specimens showed that, while most sera contained antibodies reactive with both antigens, several had reactivity only to the N 164 protein (4.2%, Table 3). Reactivity to RBD protein without reactivity to N did occur but at 165 a lower frequency (<1.2% of reactive specimens) (Table 3). When examining individual 166 specimens, although more often a high N reactivity coincided with high RBD reactivity, 167 168 many specimens had high Ab levels to one antigen but lower levels to the other (data not shown). Our recent studies showed that by adding the complete spike antigen, or by 169 replacing the RBD with the spike antigen, the sensitivity of the MIA could be even further 170 171 increased (Supplementary Table 1). However, either with just the RBD or with the spike antigen, the MIA performs comparably to other COVID-19 serology assays. In a study 172 173 looking at 500 sera, including 100 pre-COVID sera, the MIA had similar or better 174 sensitivity and specificity as three highly used commercial laboratory tests performed on the Ortho Vitros, Biomerieux Vidas, or Abbot Architect platforms (Supplementary Table 175 176 1).

Although the primary MIA developed and used for clinical testing by the DIL 177 measured total antibody, the assay proved readily adaptable to both greater multiplexing 178 of antigens and to the measurement of individual Ab isotypes. For example, the study in 179 Supplementary Figure 1 shows the multiplexing capability with simultaneous 180 measurement of Abs to the N and spike antigens of the four seasonal coronaviruses and 181 the same antigens of SARS-CoV-2 (10-plex). The study shown in Supplementary Table 182 1 and 2 shows the measurement of individual Ab isotypes. The isotype MIAs exhibited 183 the same specificity as the parent total Ab MIA (Table 1) and exhibited good sensitivity 184 which increased with time after post-symptom onset (Supplementary Table 2). 185

186 2.4 Isotype Switching in Response to SARS-CoV-2

187 Figure 4A demonstrates that there is a wide range in individual production of total Ab made to both the N and RBD antigens and shows that, even early on, some individuals 188 were highly reactive in the MIA. We more deeply investigated the onset of Ab production 189 190 by determining the kinetics and distribution of antibody classes. We assessed sera from individuals at different times from onset of COVID-19 symptoms using the isotype-specific 191 version of the MIA while examining the responses to multiple SARS-CoV-2 antigens. For 192 these studies, we not only looked at reactivity to the RBD of the spike antigen, but also 193 the entire spike and its two major domains: the amino-terminal S1 subunit of the spike, 194 which contains the RBD, and the carboxy-terminal S2 subunit. Although most of the anti-195 spike Abs appear to be directed toward S1 in most individuals, the S2 is also 196 immunogenic (Figure 4B and Supplementary Figure 2). The higher reactivity towards the 197 S1 domain, as compared to the RBD, suggests that of the S1-reactive Abs, the RBD 198

appears to be one, but not the only, focus of reactivity as measured by this assay. 199 Examination of antibody classes directed against the panel of SARS-CoV-2 target Ags 200 showed that smaller amounts of IgM antibodies were directed toward the N antigen and 201 S2 domain of the spike protein, as compared to the RBD and S1 antigens (Figure 5 and 202 Supplementary Figure 3). This was reflected both in the proportion of individuals making 203 204 Abs and the abundance of Abs. This contrasts with IgG production where we observed similar production against all the tested antigens. Likewise, we observed IgA production 205 with all the tested antigens, with, perhaps, slightly better IgA responses to the S1/RBD 206 207 region of the spike (Supplementary Figure 3).

There is clearly individual variation, with some specimens having copious amounts of 208 antibodies and early production of antibodies. However, overall there was a progressive 209 increase of total antibodies that did not peak until after 40 days post symptom onset 210 (Figure 3). In contrast with canonical kinetics of secreted Ab isotypes, we found that IgM 211 did not significantly precede the production of IgG; indeed, a higher percentage of IgG 212 positive specimens were found at the earlier times after symptom onset, as compared to 213 IgM (Figure 5). The rapid rise of IgG can be more clearly seen when looking at serial 214 215 specimens from the same individual (Figure 6). We also examined the production of IgG subclasses. We found a robust IgG1 response to all the target antigens that was induced 216 217 relatively early in the infection (Figure 7, Supplementary Figure 4). IgG3 production was also robust, albeit slightly delayed. In contrast, only a small percentage of specimens 218 219 contained detectable IgG2 and IgG4. Detectable IgG4 production appeared to be restricted to the nucleocapsid antigen (Figure 7, Supplementary Figure 4). 220

221 **3.** Discussion

This report describes the overall experience of the Wadsworth Center's approach 222 223 in developing serology testing to determine prior SARS-CoV-2 virus exposure. The test 224 was developed to address an emergency public health need in New York, which initially had the highest number of COVID-19 cases in the US (11). While not the first US clinical 225 226 COVID-19 serology assay to receive FDA EUA, ours was the first microsphere-based assay to receive EUA ((12) and EUA: https://www.fda.gov/media/137541/download). 227 Other MIAs have also been described for use in research studies (e.g., (13, 14)) and, for 228 229 clinical testing, Luminex Corp subsequently received EUA for its MIA (12). It was reassuring that, despite our initial MIA being based on the SARS-CoV-1 N antigen, it 230 231 showed good result agreement with the first EUA ELISA, based on the SARS-CoV-2 RBD target antigen, developed by the Krammer laboratory (15, 16). However, this should not 232 have been surprising, given the high degree of antigenic cross-reactivity between the N 233 234 antigens of the two viruses. That cross-reactivity also reflects the degree of amino acid homology (90%) (8), as does the lower cross-reactivity observed between the spike 235 antigens of SARS-CoV-1 and SARS-CoV-2 (76% amino acid homology) (8). 236

Amino acid homology between the N or spike antigens of SARS-CoV-2 and their counterparts of the four seasonal coronaviruses is <50% (17), and, likewise, none of the common coronaviruses interfere with the SARS-CoV-2 MIA. It is interesting however, that, although normal sera contain abundant antibodies to the common coronaviruses, we only found significant reactivity when assessing sera from individuals recently infected with respiratory viruses, including common coronaviruses. Whether this reflects induced

cross-reactive antigens or is a consequence of inflammation associated with the acute 243 infections, is currently unclear. It is notable that increases in antibodies reactive with 244 common coronaviruses also occur in acute COVID-19 infections. Acute respiratory 245 infection sera are not usually included when determining assay specificity, but, if 246 generalizable to other assays, the interference with the COVID response should be 247 248 considered when using highly sensitive tests when both HuCoV's and influenza infections are prevalent. With respect to our SARS-CoV-2 MIA, these sera prompted us to raise the 249 assay threshold and sacrifice some sensitivity (ultimately, 92.2% versus 95.9% using only 250 251 the N antigens; 94.9% versus 97.1% using multiplexed N and RBD antigens). The sensitivity is improved over that of the original assay, due to not only the addition of the 252 N antigen, but also the testing of specimen that had been collected at a later time point 253 after symptom onset. As measured by our MIA, the COVID antibody response over a 254 broad group of individuals was slower than expected, with the highest percentages of Ab-255 positive individuals occurring after 21 days. Further, a small number of individuals did not 256 appear to make substantial amounts of antibodies in response to infection. Even at the 3 257 SD level, 2.7% of the specimens were negative in this study. It is likely that these are 258 259 individuals who truly failed to mount a large Ab response to the virus. In an examination of >27,000 convalescent sera, we identified donors who had been tested up to 8 times 260 261 over a 6-month period, with certain individuals having consistently undetectable Ab levels 262 in the MIA (unpublished observations). Given that these represent convalescent individuals, it appears that in some instances, COVID-19 can be resolved with minimal 263 264 antibody production, presumably solely through cell-mediated immunity. This conclusion 265 would be consistent with studies showing that, although neutralizing antibody plays a 13

predominant role, T cells can contribute to protection when antibody levels are suboptimal(18-20).

268 Since the pandemic began, numerous serology tests have been developed and 269 implemented for both research and clinical testing. To date, over 60 individual serology assays have received EUA (12). These tests measure antibodies to a variety of target 270 271 antigens and generally measure total antibody or IgG (with or without separate detection of IgM). Most tests identify antibodies reactive with either the N antigen or a version of 272 the spike protein (RBD, S1, or full trimeric spike). However, the abundance of antibodies 273 274 to the N protein or spike protein are independent of each other and an individual serum might have strong reactivity to one antigen with poor or absent reactivity to the other. This 275 276 may make result comparisons between different assays difficult. The detection of only one or the other Ag reactivity is an important consideration when comparing performance 277 of assays that use different target antigens. An advantage of the MIA is that antigens can 278 be easily and routinely multiplexed. For example, we show here simultaneous 279 measurements of antibodies reactive with the N, S1, S2, RBD, trimeric spike, and 280 seasonal coronavirus N plus spike antigens in a single specimen. Examination of specific 281 282 antibody responses to each antigen may also be important for identifying severity parameters of COVID-19. For example, Atyeo et al suggest that strong early Ab 283 responses to the N antigen are associated with high disease severity (21) and Ng et al 284 suggest that cross-reactivity to the S2 domain of the spike antigen of common 285 coronaviruses might offer some degree of protection from SARS-COV-2 infection (22). 286 Multiplexing the N and spike antigens may also be useful for distinguishing natural 287

infection from (spike-based) vaccination responses, as it would be expected that only infection would lead to the presence of antibodies reactive with the N antigen. However, caution should be used in solely relying upon the differential presence of anti-N and antispike Abs. Aside from individual variation, timing of collection may be important as some studies have shown that the duration of anti-N Abs is shorter than anti-spike Abs (23). In these cases, spike reactivity without N antigen reactivity might mistakenly be reported as a response to vaccination with a spike-based vaccine.

The MIA is readily adaptable to measuring responses of different lg isotypes, 295 296 different specimen matrices, and high throughput analyses. For example, our laboratory has used the MIA to detect IgM antibodies reactive with the SARS-CoV-2 N, RBD, and 297 full-length spike in both newborn serum and adult CSF to suggest in situ infections ((24) 298 and unpublished observations). However, isotype analyses may have their highest value 299 in delineating the stage of infection. Although the full kinetics of antibody persistence, 300 301 including isotypes, has yet to be determined, it might be expected that the presence of IgM would be indicative of a more recent infection, whereas IgG alone might indicate 302 either a remote infection or a vaccine response. In terms of our own analyses of antibody 303 304 isotypes at early points after the onset of infection, we noted the early onset of robust IgG production relative to a more canonical antibody induction pattern. The quick production 305 of IgG has been observed by others (25-27). The two individuals shown in Figure 6 306 showed a rapid rise in IgG reactive with both the N and RBD antigens, relative to IgM and 307 IgA. Both of those people were hospitalized and on ventilators at the time of blood 308 collection. Our results are consistent with measurements on the same two individuals as 309

reported by Yang et al, where IgM and IgG, also reactive with the N and RBD antigens, 310 were assessed using a different assay system (Pylon COVID-19 IgM and IgG cyclic 311 fluorescence assay) (27). That study examined a larger group and found that for most 312 individuals, IgG was detected coincidentally or prior to IgM detection and that there was 313 no significant difference associated with disease severity. This pattern, as illustrated by 314 315 Figure 6, resembles a canonical secondary antibody response. As opposed to B cells, SARS-CoV-2 cross-reactive memory T cells, originating from prior infection with seasonal 316 coronaviruses, have been identified (28). It is tempting to speculate that these cells help 317 SARS-CoV-2-specific B cells and drive immediate antibody class switching. However, it 318 is also possible that switch and heightened production of IgG is due to the general 319 extensive inflammation caused by virus infection. It is also possible that the IgG 320 antibodies produced are of higher affinity than the IgM and thus, may be more easily 321 detectable in immunoassays. 322

Our purpose in developing the NYS COVID MIA was to engage in clinical testing 323 for COVID Abs. To that end, we have tested both clinical specimens for assessment of 324 patient responses to SARS-COV-2 and we have also tested more than 27,000 sera of 325 326 potential donors of convalescent plasma. The assay has been further modified to detect Abs in dried blood spots and used in high throughput immunosurveillance studies to 327 monitor SARS-CoV-2 exposure in New York State (29). The MIA continues to evolve 328 through evaluation and possible addition of spike antigens from variants of concern. 329 Further, for the convalescent plasma screening effort, we currently are aligning the MIA 330 Index values with virus neutralization values to better identify "high titer" neutralizing 331

- 332 plasma. Finally, our future efforts will include validation of the MIA using standardized
- sera, including the WHO International Standard (https://www.nibsc.org/documents/ifu/20-
- 136.pdf), so that results can be harmonized and reported as quantitative Binding Antibody
- 335 Units.
- 336

337 4. Materials and Methods

338 4.1. COVID-19 Serum Samples

Studies were performed on sera from deidentified specimens submitted to the New York 339 State Department of Health in response to a broad request for assay development and 340 validations. The request was initially made prior to and just following the first reported 341 COVID-19 case in New York (March 1, 2020). The following institutions submitted serum 342 specimens after RT-PCR confirmation of SARS-CoV-2 infection: Northwell Hospital 343 344 Systems, University of Rochester Medical Center, Columbia University Medical Center, New York Presbyterian/Weill Cornell Medical Center, New York Presbyterian Hospital 345 (NYPH)/Columbia University (CUMC) and Weill Cornell Medical Center (WCMC), and 346 Mount Sinai Health System. These submitted specimens were "early acute" (collected 1-347 25 days post onset of symptoms). Some acute specimens (collected 1-25 days post onset 348 of symptoms) were from COVID-19 hospitalized individuals at NYPH/WCMC. Additional 349 specimens, obtained from the New York Blood Center, were sera obtained from healthy, 350 convalescent patients who had recovered from COVID-19 >14 days prior to serum 351 collection. These specimens were from individuals volunteering to be tested as potential 352 donors of plasma for passive Ab transfer. All specimens were stored at 4°C until testing 353 was completed (<1 week) and transferred to -80°C for long-term storage. Aliquots were 354 made to minimize freeze-thaw. All testing and archiving of human specimens were done 355 under a declared New York State Public Health Emergency and also approved by 356 357 NYSDOH Institutional Review Board (IRB 20-021). Guinea pig antiserum reactive with 358 SARS-CoV-1 was purchased from BEI Resources (Manassas, VA).

359 4.2 Non-COVID-19 Serum Samples

Specificity and control serum panels were deidentified specimens consisting of 1) an equal representation from presumed healthy individuals and received prior to 2019 that were obtained from (downstate New York) the New York Blood Center or (upstate New York) the American Red Cross; 2) positive identification for known pathogens or autoantigens and obtained through purchase, donation, or submission for clinical testing; and, 3) acute phase (non-COVID-19) respiratory infection obtained from NYPH/WCMC . For the last, where indicated, the agent of infection was identified using molecular testing.

367 4.3 Reagents

For MIAs, wash buffer and phosphate buffered saline pH 7.4, 0.05% sodium azide (PBS-368 369 TN) were purchased from Sigma (Sigma Aldrich, St. Louis, MO). Chemicals, 1-ethyl-3-(3dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide 370 (sulfo-NHS), were supplied by Pierce Chemicals (Pierce, Rockford, IL). Microspheres, 371 calibration microspheres, and sheath fluid were obtained from Luminex Corporation 372 (Luminex Corp., Austin, TX). R-phycoerythrin (PE)-conjugated goat anti-human Ig, goat 373 anti-human IgG, anti-human IgM, anti-human IgA, mouse anti-human IgG1, mouse anti-374 human IgG2, mouse anti-human IgG3, and mouse anti-human IgG4 were purchased 375 (Southern Biotech). Recombinant SARS-CoV-2 nucleocapsid and spike S2 domain were 376 377 purchased (Native Antigen, Oxfordshire, UK). Recombinant nucleocapsid and spike antigens from the common human coronaviruses (OC43, 229E, HKU-1, NL-63) were 378 purchased (Native Antigen, Oxfordshire, UK). Recombinant SARS-CoV-2 RBD and spike 379 380 S1 domain were provided by MassBiologics (Boston, MA), and produced as described

below. Recombinant SARS-1 nucleocapsid was produced at the Wadsworth Center as
described below. For some experiments, SARS CoV-2 RBD was also a kind gift from Dr.
Florian Krammer, (Mount Sinai Health System). SARS-CoV-1 spike proteins were
purchased from BEI Resources (Manassas, VA).

385 4.4 Recombinant Antigens

The amino-acid sequence of the SARS-CoV-2 S glycoprotein sequence (GeneBank: 386 MN908947) were used to design a codon-optimized version for mammalian cell 387 388 expression. The synthetic gene encoding the Receptor Binding Domain (RBD) a.a. 319-541 and S1 subunit a.a. 1-604 of the S glycoproteins were cloned into pcDNA 3.1 Myc/His 389 in-frame with c-Myc and 6-histidine epitope tags that enabled detection and purification. 390 391 The cloned genes were sequenced to confirm that no errors had accumulated during the cloning process. All constructs were transfected into Expi293 cells using ExpiFectamine 392 293 Transfection Kit (Thermo Fisher), and recombinant proteins were purified by 393 immobilized metal chelate affinity chromatography using nickel-nitrilotriacetic acid (Ni-394 NTA) agarose beads. Proteins were eluted from the columns using 250 mmol/L imidazole 395 and then dialyzed into phosphate-buffered saline (PBS), pH 7.2 and checked for size and 396 purity by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). For 397 production of the recombinant SARS-CoV-1 Nucleocapsid protein, a cDNA copy of the N 398 gene of SARS-CoV was produced by reverse transcription-PCR of RNA purified from 399 Vero E6 cells that had been infected with SARS-CoV (strain Urbani; GenBank accession 400 number AY278741). The N gene cDNA was ligated into the bacterial expression vector 401 pET-28a(+) (Novagen (Merck-Millipore) Burlington,MA) for expression of carboxy-402

terminal His6-tagged full-length N protein. Following induction in RosettaTM
BL21(DE3)pLysS E. coli cells (Novagen (Merck-Millipore) Burlington,MA), his-tagged N
protein was purified by metal chelation chromatography on a Ni-NTA column (Novagen
(Merck-Millipore) Burlington,MA). The purified N protein migrated in SDS-PAGE in accord
with its predicted molecular mass of 47.1 kDa and was estimated to be greater than 98%
pure.

409 4.5. Microsphere Immunoassay (MIA)

Specimens were assessed for the presence of reactive antibodies using an MIA modified 410 from a previously described procedure (30). Briefly, recombinant antigens were covalently 411 linked to the surface of fluorescent microspheres (Luminex Corporation, Austin, TX). 412 Serum samples (25 µL at 1:100 dilution) and antigen-conjugated microspheres (25 µL at 413 5x10⁴ microspheres/mL) were mixed and incubated 30 minutes at 37°C before washing 414 and further incubation with phycoerythrin (PE)-conjugated secondary antibody. The PE-415 conjugated antibodies were chosen to specifically recognize, as indicated, total antibodies 416 (pan-lg), or, individually IgM, IgA, IgG, IgG1, IgG2, IgG3, IgG4. After washing and final 417 resuspension in buffer, the samples were analyzed on a FlexMap 3D analyzer using 418 xPONENT software, version 4.3 (Luminex Corporation, Austin, TX). 419

420 4.6 High-throughput Instrument Detection of Antibodies to SARS-CoV-2

421 Specimens were assessed for the presence of reactive antibodies using: 1) the Ortho-422 Clinical Diagnostics (Rochester, NY) Vitros anti-SARS-CoV-2 IgG chemiluminescent 423 immunoassay; 2) the Abbott Laboratories (Abbott Park, IL) SARS-CoV-2 IgG

chemiluminescent microparticle immunoassay); 3) the bioMerieux (Durham, North 424 Carolina) VIDAS SARS-COV-2 IgG immunoassay. The Abbott Laboratories SARS-CoV-425 2 IgG assay is a gualitative chemiluminescence test that we performed on the Abbott 426 Architect i1000SR automated immunoassay analyzer. The target antigen is the SARS-427 CoV-2 N protein and only IgG antibodies were measured. Testing was performed in 428 429 accordance with the manufacturer's instructions using undiluted serum. The FDA EUA listed performance characteristics are: Sensitivity, 100% (95.8%- 100%); Specificity, 430 99.6% (99.0% - 99.9%). The Ortho-Clinical Diagnostics anti-SARS-CoV-2 IgG assay is a 431 432 qualitative chemiluminescence test that we performed on the Ortho Vitros 5600 automated immunoassay analyzer. The target antigen is the S1 subunit of the SARS-433 CoV-2 spike protein and only IgG antibodies were measured. Testing was performed in 434 accordance with the manufacturer's instructions using undiluted serum. The FDA EUA 435 listed performance characteristics are: Sensitivity, 90.0% (76.9% - 96.0%); Specificity, 436 100% (99.1% - 100%). The bioMerieux VIDAS SARS-COV-2 IgG immunoassay is a 437 qualitative enzyme-linked fluorescence assay that we performed on the Vidas-3 438 automated analyzer. The target antigen is the RBD of the SARS-CoV-2 spike protein 439 440 and only IgG antibodies were measured. Testing was performed in accordance with the manufacturer's instructions using undiluted serum. The FDA EUA listed performance 441 442 characteristics are: Sensitivity, 100% (88.3 - 100%); Specificity, 99.9% (99.4% - 100%).

443 4.7 Reporting of Statistical Methods

All graphs and statistical analyses to determine Spearman's rank correlation coefficients
 were done using Prism 9.0 (Graphpad, San Diego, CA). Spearman's correlations were
 calculated using all complete pairs of variables in the dataset.

447

448 6. Acknowledgments.

The authors would like to acknowledge and thank the following Wadsworth Center 449 laboratory members for their expert technical assistance: June Chan, Margaux Hales. 450 Colleen Walsh, Geraldine Quinones, Brian Grimwood. We thank Dr. Lili Kuo her advice 451 and insights on the expression of viral proteins. We especially thank Drs. Susan Wong 452 and Paul Masters for their helpful advice and their critical reading of this manuscript and 453 Dr. Steven Spitalnik for support and advice. We would like to acknowledge the 454 Wadsworth Center core facilities that contributed to this work: WC Tissue Culture and 455 Media Core and the WC Sequencing Core. 456

457

458 **7. Funding Sources**

The authors have no conflicting interests relevant to this study. This work was performed 459 in part under a Project Award Agreement from the National Institute for Innovation in 460 Biopharmaceuticals (NIIMBL) and financial 461 Manufacturing assistance award 462 70NANB20H037 from the U.S. Department of Commerce, National Institute of Standards and Technology. Additional support was provided by a grant (P20-000271) from the New 463 York Community Trust. A portion of the work described in this publication was supported 464

465	by Co	operative Agreement Number NU50CK000516 from the Centers of Disease Control
466	and F	revention. Its contents are solely the responsibility of the authors and do not
467	neces	sarily represent the official views of the Centers for Disease Control and Prevention.
468		
469	8.	References
470	1.	Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of
471	global	health concern. Lancet. 2020;395(10223):470-3.
472	2.	Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia
473	outbre	ak associated with a new coronavirus of probable bat origin. Nature.
474	2020;	579(7798):270-3.
475	3.	Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-
476	econo	mic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg.
477	2020;	78:185-93.
478	4.	Mofijur M, Fattah IMR, Alam MA, Islam A, Ong HC, Rahman SMA, et al. Impact
479	of CO	VID-19 on the social, economic, environmental and energy domains: Lessons
480	learnt	from a global pandemic. Sustain Prod Consum. 2021;26:343-59.
481	5.	Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, et al. Evolutionary
482	origins	of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19
483	pande	mic. Nat Microbiol. 2020;5(11):1408-17.
484	6.	Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick L, Rattigan
485	SM, e	t al. A systematic review of antibody mediated immunity to coronaviruses: 24

antibody kinetics, correlates of protection, and association of antibody responses with
severity of disease. medRxiv. 2020:2020.04.14.20065771.

488 7. Pecora ND, Zand MS. Measuring the Serologic Response to Severe Acute

489 Respiratory Syndrome Coronavirus 2: Methods and Meaning. Clin Lab Med.

490 2020;40(4):603-14.

491 8. Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic Comparison

492 of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-

493 CoV. Viruses. 2020;12(2).

494 9. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a

495 possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-25.

496 10. Monto AS, DeJonge PM, Callear AP, Bazzi LA, Capriola SB, Malosh RE, et al.

497 Coronavirus Occurrence and Transmission Over 8 Years in the HIVE Cohort of

Households in Michigan. J Infect Dis. 2020;222(1):9-16.

499 11. New York State Coronavirus Tracker [Available from:

500 https://coronavirus.health.ny.gov/home.

12. Administration USFaD. Individual EUAs for Serology and Other Adaptive Immune

502 Response Tests for SARS-CoV-2 2021 [Available from: https://www.fda.gov/medical-

503 devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-

504 devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-

sars-cov-2#individual-serological.

13. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al.
COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in
Saliva. J Clin Microbiol. 2020;59(1).

509 14. Sholukh AM, Fiore-Gartland A, Ford ES, Hou Y, Tse LV, Lempp FA, et al.

510 Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural

511 infection and vaccine trials. medRxiv. 2020.

15. Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M,

et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv.

514 2020:2020.03.17.20037713.

16. Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF, Wong SJ, et al.

516 Neutralizing Antibody Responses in COVID-19 Convalescent Sera. J Infect Dis.

517 2021;223(1):47-55.

17. Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson JP, et

al. Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal

520 Betacoronaviruses. J Clin Immunol. 2021:1-8.

18. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf

522 D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and

523 Associations with Age and Disease Severity. Cell. 2020.

524 19. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell.
525 2021;184(4):861-80.

McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al.
Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature.
2021;590(7847):630-4.

529 21. Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct Early
530 Serological Signatures Track with SARS-CoV-2 Survival. Immunity. 2020;53(3):524531 32.e4.

532 22. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al.

533 Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science.

534 2020;370(6522):1339-43.

535 23. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, et al. Changes in

536 SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of

537 Infections in Population-Based Seroprevalence Studies. J Virol. 2021;95(3).

538 24. Gupta A, Malhotra Y, Patil U, Muradas AR, Lee WT, Krammer F, et al. In Utero

Vertical Transmission of Coronavirus Disease 2019 in a Severely III 29-week Preterm
Infant. AJP Rep. 2020;10(3):e270-e4.

541 25. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to

542 SARS-CoV-2 in patients of novel coronavirus disease 2019. medRxiv.

543 2020:2020.03.02.20030189.

544 26. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2

specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect.

546 2020;9(1):940-8.

 548 CoV-2 antibody characterization in emergency department, hospitalized and 549 convalescent patients by two semi-quantitative immunoassays. Clin Chim Acta. 550 2020;509:117-25. 551 28. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, 552 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID- 	547	27. Yang HS, Racine-Brzostek SE, Lee WT, Hunt D, Yee J, Chen Z, et al. SARS-
 convalescent patients by two semi-quantitative immunoassays. Clin Chim Acta. 2020;509:117-25. 28. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID- 	548	CoV-2 antibody characterization in emergency department, hospitalized and
 2020;509:117-25. 28. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID- 	549	convalescent patients by two semi-quantitative immunoassays. Clin Chim Acta.
 Since 28. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID- 	550	2020;509:117-25.
552 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-	551	28. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al.
	552	Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19

disease and unexposed individuals. Cell. 2020.

29. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM,

et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann

556 Epidemiol. 2020;48:23-9.e4.

30. Wong SJ, Demarest VL, Boyle RH, Wang T, Ledizet M, Kar K, et al. Detection of
human anti-flavivirus antibodies with a west nile virus recombinant antigen microsphere
immunoassay. J Clin Microbiol. 2004;42(1):65-72.

561 10. Figure Legends

562	Figure 1	Cross-reactivity between SARS-1 and SARS CoV-2 Nucleocapsid and
563		Spike antigens. Sera from nonimmune or SARS-CoV-1-immunized
564		guinea pigs (<i>A</i> , <i>D</i>), a COVID-19 convalescent individual (<i>B</i> , <i>E</i>) or a panel of
565		sera from COVID convalescent individuals (C,F) were diluted and
566		measured in a MIA for total binding antibodies against the Nucleocapsid
567		(top row) and Spike antigens (bottom row) from either SARS-1 or SARS-
568		CoV-2. Binding activity is indicated by the median fluorescence intensities
569		(MFI).

571	Figure 2	Determination of NYS SARS MIA specificity. (A) Serum specimens
572		collected in 2009 from healthy blood donors (American Red Cross in
573		Syracuse, NY, and New York Blood Center in New York City, NY),
574		representing pre-COVID samples or (B) specimens collected in 2020 from
575		hospitalized SARS-CoV-2 RT-PCR negative individuals with molecular
576		determination of infection with non-SARS-CoV-2 respiratory viruses; or (C)
577		specimens collected in 2020 from COVID-19 convalescent individuals were
578		assessed using the NYS SARS MIA (SARS-1 N antigen target) for total
579		antibody reactivity. Shown are results of individual samples. On the far right
580		is a bar showing the reported interpretative results of (<i>blue</i>) Reactive, (<i>Red</i>)
581		Indeterminate or (gray) Nonreactive.

582

Figure 3 **Detection of N antigen reactivity by MIA**. Serum specimens from 583 individuals with SARS-CoV-2 infections, confirmed using RT-PCR, and 584 reported symptom onset dates were assessed for total antibodies to the 585 SARS-1 N antigen. Each point represents the reactivity of a single 586 individual with the mean MFI of the group at each time point indicated by a 587 588 black bar. The gray bar at the top left indicates the data accumulated for the initial submission of the MIA for FDA EUA with assay sensitivity determined 589 as the percentage of specimens reactive at ≥ 6 SD above the cutoff. 590

591

Figure 4 Reactivity to different SARS-CoV-2 target antigens as determined by 592 MIA. Serum specimens from individuals with SARS-CoV-2 infections, 593 confirmed using RT-PCR, and reported symptom onset dates were 594 assessed for total antibodies to the SARS-CoV-1 spike antigen or different 595 SARS-CoV-2 target antigens (Nucleocapsid, complete spike, and separate 596 spike components (RBD, S1 subunit, S2 subunit). Reactivity is expressed 597 as an Index value where a value of 1.0 is 3 SD above the cutoff for the 598 individual target antigen and positivity being the Index value that is ≥ 6 SD 599 above the cutoff for the individual target antigen. (A) The reactivity in the 600 601 same sera to Nucleocapsid and RBD antigens at different times after onset of symptoms shown for individuals or as a percent of the total sera (far right 602

panel). (*B*) Relative binding to multiplexed antigens in the sera of 10 COVID19 convalescent individuals (means + SD).

605

Figure 5 **Production of different antibody classes reactive with SARS-CoV-2 target antigens**. Serum specimens from individuals with SARS-CoV-2 infections, confirmed using RT-PCR, and reported symptom onset dates were assessed for total antibody, IgM, IgG, and IgA antibodies to different SARS-CoV-2 target antigens (Nucleocapsid, full spike, and separate spike components (RBD, S1 subunit, S2 subunit). Shown are the percentages of positive specimens for each class to the individual target antigens.

613

614 Figure 6 Kinetics of different antibody class production in COVID-19 individuals. Serum specimens from two individuals hospitalized with 615 SARS-CoV-2 infections were collected on different days after reported 616 symptom onset dates and were assessed for IgG1, IgG2, IgG3, and 617 antibodies to different SARS-CoV-2 target antigens (Nucleocapsid, and 618 separate spike components (RBD, S1 subunit, S2 subunit). Shown are the 619 620 percentages of positive specimens for each class to the individual target antigens. 621

622

Figure 7 Production of different IgG subclasses reactive with SARS-CoV-2 target antigens in the MIA. Serum specimens from individuals with SARS-CoV-2 infections, confirmed using RT-PCR, and reported symptom onset dates were assessed for IgG1, IgG2, IgG3, and IgG4 antibodies to SARS-CoV-2 nucleocapsid, spike antigen and spike components: RBD, S1, and S2 target antigens. Shown are the percentages of positive specimens for each class to the individual target antigens



Figure 1



Figure 2











Figure 6



	Non-Reactivity (95%CI) in the MIA (N plus RBD)				
	Ig	IgM	IgG	IgA	
Blood Donors	240/244 (98.4%)	248/257 (96.5%)	254/257 (98.8%)	182/186 (97.8%)	
	(95.9-99.4)	(93.5-98.2)	(96.6-99.7)	(94.6-99.2)	
Diverse Group	77/78 (98.7%)	74/78 (94.9%)	76/78 (97.4%)	77/78 (98.7%)	
of Analytes	(93.1-99.9)	(87.5-98.0)	(91.1-99.5)	(93.1-99.9)	

Table 1. Determination of MIA Specificity. Sera collections were used to evaluate total antibody (Ig) or isotype-specific binding to either the SARS-CoV-2 N protein or the RBD of the spike protein in a multiplexed MIA: (top) 182-257 serum samples collected in 2009 from healthy blood donors (American Red Cross in Syracuse, NY, and New York Blood Center in New York City, NY), representing pre-COVID samples; (bottom) 78 serum samples with known antibody reactivity to a diverse group of viral pathogens (Chikungunya, dengue, HCV, HIV, measles, mumps, rubella, VZV, West Nile virus, herpes simplex, Zika virus, enteroviruses, HBV, cytomegalovirus, Epstein Barr, Eastern Equine Encephalitis, and Yellow Fever viruses), as well as sera with Antinuclear antibodies and Rheumatoid Factor. Shown are the numbers (percentages) of MIA negative/total specimens and the 95% Confidence Intervals. "Negative" means non-reactive to both target antigens in the specimen; "indeterminate" means indeterminant to one target antigen and indeterminant or non-reactive to the other target antigen in the specimen. For this analysis, indeterminates and negatives are counted together, using a threshold of 6 SD above the mean MFI of 92 normal sera to determine positivity.

Total Antibody binding to N plus RBD							
Days from	Samples tested	RT- PCR	NY SARS-CoV MIA Result as Compared to PCR			Sensitivity (95%CD	
onset	(N)	(N) result Po		Indeterminate	Negative		
7 – 15	48	Pos	23	7	18	23/48 47.9% (34.47% - 61.67%)	
16 - 25	17	Pos	14	0	3	14/17 82.4% (58.97% - 93.81%)	
26-30	28	Pos	27	1	0	27/28 96.4% (82.29% - 99.82%)	
Total	93						

Table 2. Determination of MIA Sensitivity. A total of 93 serum specimens from individuals with SARS-CoV-2 infections, confirmed using RT-PCR, and reported symptom onset dates were assessed for total antibodies to the SARS-CoV-2 Nucleocapsid antigen and the RBD. A positive specimen is \geq 6 SD above the cutoff for either one of the target antigens; an indeterminate is \geq 3 SD above the cutoff for either or both of the target antigens; a negative is a sample with no reactivity to either target antigen. Sensitivity at different period post symptom onset is shown on the right as the number of MIA-positive specimens/total specimens tested.

Convalescent Serum Specimens	Number	Percentage
Total Tested	8659	100
N and RBD (Both Reactive or Indeterminate in the same sample)	7980	92.2
N (Reactive or Indeterminate) with RBD (Nonreactive)	365	4.2
RBD (Reactive or Indeterminate) with N (Nonreactive)	101	1.2
Both antigens Nonreactive	238	2.7
One or both antigen Indeterminate (<i>clinical*</i>)	192	2.2
Using N only, Positive @6 SD (clinical*)	7986	92.2
Using N only, Positive @3 SD	8304	95.9
Using N and RBD**, Positive @6 SD (<i>clinical</i> *)	8219	94.9
Using N and RBD**, Positive @3 SD	8411	97.1

Table 3. Reactivity to the SARS-COV-2 N and RBD antigens. 8659 serum specimens from convalescent COVID-19 donors who were at least 14 days removed from symptom onset were tested using the MIA for total antibody reactivity to the SARS-COV-2 and RBD antigens. A reactive specimen is \geq 6 SD above the cutoff; an indeterminate is \geq 3 SD above the cutoff. The bottom four rows indicate assay reported results calculated to show positivity at 3SD or 6 SD thresholds and shows the effect of using the single N target Ag versus both target Ags. * Threshold used for reporting "Reactive" specimens in diagnostic assays. **One or both target Ags reactive.